TRPM4 and prostate carcinoma: TRPM4, a calcium‐activated monovalent‐selective cation channel (Guinamard et al., 2010; Launay et al., 2002), has been found to be overexpressed in a variety of human tumors, including prostate cancer (Berg et al., 2016; Holzmann et al., 2015; Prevarskaya et al., 2007; Suguro et al., 2006).